<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="brief-report" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?properties open_access?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Front Psychiatry</journal-id>
<journal-id journal-id-type="iso-abbrev">Front Psychiatry</journal-id>
<journal-id journal-id-type="publisher-id">Front. Psychiatry</journal-id>
<journal-title-group>
<journal-title>Frontiers in Psychiatry</journal-title>
</journal-title-group>
<issn pub-type="epub">1664-0640</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">28507523</article-id>
<article-id pub-id-type="pmc">5410649</article-id>
<article-id pub-id-type="doi">10.3389/fpsyt.2017.00069</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Psychiatry</subject>
<subj-group>
<subject>Perspective</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Autism Spectrum Disorders and Schizophrenia Spectrum Disorders: Excitation/Inhibition Imbalance and Developmental Trajectories</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Canitano</surname>
<given-names>Roberto</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="corresp" rid="cor1">*</xref>
<uri xlink:href="http://frontiersin.org/people/u/76472" xlink:type="simple"></uri>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Pallagrosi</surname>
<given-names>Mauro</given-names>
</name>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
</contrib>
</contrib-group>
<aff id="aff1"><sup>1</sup><institution>Division of Child Neuropsychiatry, University Hospital of Siena</institution>, <addr-line>Siena</addr-line>, <country>Italy</country></aff>
<aff id="aff2"><sup>2</sup><institution>Department of Psychiatry, Sapienza University of Rome</institution>, <addr-line>Rome</addr-line>, <country>Italy</country></aff>
<author-notes>
<fn fn-type="edited-by">
<p>Edited by: Ashok Mysore, St. John’s Medical College Hospital, India</p>
</fn>
<fn fn-type="edited-by">
<p>Reviewed by: Joseph Gonzalez-Heydrich, Harvard Medical School, USA; Bart P. F. Rutten, Maastricht University, Netherlands</p>
</fn>
<corresp content-type="corresp" id="cor1">*Correspondence: Roberto Canitano, <email>r.canitano@ao-siena.toscana.it</email>, <email>canitano@unisi.it</email></corresp>
<fn fn-type="other" id="fn002">
<p>Specialty section: This article was submitted to Child and Adolescent Psychiatry, a section of the journal Frontiers in Psychiatry</p>
</fn>
</author-notes>
<pub-date pub-type="epub">
<day>01</day>
<month>5</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="collection">
<year>2017</year>
</pub-date>
<volume>8</volume>
<elocation-id>69</elocation-id>
<history>
<date date-type="received">
<day>05</day>
<month>8</month>
<year>2016</year>
</date>
<date date-type="accepted">
<day>10</day>
<month>4</month>
<year>2017</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright © 2017 Canitano and Pallagrosi.</copyright-statement>
<copyright-year>2017</copyright-year>
<copyright-holder>Canitano and Pallagrosi</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/">
<license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p>
</license>
</permissions>
<abstract>
<p>Autism spectrum disorders (ASD) and schizophrenia spectrum disorders (SSD) share clinical and genetic components that have long been recognized. The two disorders co-occur more frequently than would be predicted by their respective prevalence, suggesting that a complex, multifactor association is involved. However, DSM-5 maintains the distinction between ASD, with core social and communication impairments, and SSD, including schizophrenia (SCZ), with hallucinations, delusions, and thought disorder as essential features. ASD and SSD have common biological underpinnings that may emerge early in development and unfold over time. One of the hypotheses supporting the similarities in the social and cognitive disturbances of ASD and SSD relates to abnormalities in the ratio of excitatory to inhibitory cortical activity (E/I imbalance). E/I imbalance in neurodevelopmental disorders could be the consequence of abnormalities in genes coding for glutamatergic and GABAergic receptors or synaptic proteins followed by system derangements. SSD and ASD have been characterized as polygenic disorders in which to the onset and progression of disease is triggered by interactions among multiple genes. Mammalian target of rapamycin signaling is under intense investigation as a convergent altered pathway in the two spectrum disorders. Current understanding of shared and divergent patterns between ASD and SSD from molecular to clinical aspects is still incomplete and may be implemented by the research domain criteria approach.</p>
</abstract>
<kwd-group>
<kwd>autism spectrum disorders</kwd>
<kwd>schizophrenia spectrum disorders</kwd>
<kwd>psychosis</kwd>
<kwd>children and adolescents</kwd>
<kwd>excitation/inhibition imbalance</kwd>
</kwd-group>
<counts>
<fig-count count="0"></fig-count>
<table-count count="2"></table-count>
<equation-count count="0"></equation-count>
<ref-count count="60"></ref-count>
<page-count count="7"></page-count>
<word-count count="5307"></word-count>
</counts>
</article-meta>
</front>
<body>
<sec id="S1">
<title>Autism Spectrum Disorder (ASD) and Schizophrenia Spectrum Disorder (SSD): Current Understanding</title>
<p>The clinical interplay and overlap between SSD and ASD have long been recognized as the two classes of disorder that share phenotypic and clinical features and a number of individuals diagnosed with ASD subsequently develop SSD symptoms (<xref ref-type="bibr" rid="B1">1</xref>). Currently, the relationship is further emphasized after controversies on the shared patterns and differences of the two disorders.</p>
<p>It has been demonstrated that the two types of disorder co-occur more frequently than would be that predicted by their respective prevalence. DSM-5 maintains a nosological distinction between ASD and schizophrenia (SCZ) in spite of overlapping in clinical characteristics. Examining the specific definition of core symptoms, there are two major criteria for ASD: “(1) persistent deficits in social communication, social interactions, social-emotional reciprocity and communicative behaviors and (2) restricted, repetitive patterns of behavior, interests or activities, including stereotyped or repetitive movements, behavioral rigidity, odd or intense interests,” and as an important additional criterion, abnormally high or low reactivity to sensory stimuli. On the other hand, the DSM-5 diagnostic criteria for SCZ specify that at least two of the following symptoms must be present: “hallucinations, delusions, disorganized speech, grossly disorganized or catatonic behavior and negative symptoms.” Furthermore, in DSM-5, the criteria have been reorganized to emphasize the variability in the severity of the psychopathology and the severity dimensions have been updated (<xref ref-type="bibr" rid="B2">2</xref>).</p>
<p>Childhood-onset schizophrenia (COS) is a subtype of SCZ defined by onset of psychotic symptoms before 13 years and the absence of any other neuropsychiatric diagnosis. Re-examination of the overlap between COS and ASD has highlighted the clinical and genetic commonalities. Remarkably, in almost half the cases of COS identified in the largest longitudinal study to date, a pervasive developmental disorder was present before the onset of psychosis (<xref ref-type="bibr" rid="B3">3</xref>). In contrast, and somewhat unexpectedly, prospective longitudinal studies following children with ASD into young adulthood rarely report the appearance of psychotic symptoms. SSD includes SCZ, schizofreniform disorder, schizoaffective disorder, and schizotypal personality disorder. In ASD, it is not rare to detect unusual preoccupations, unusual perceptual experiences, odd thinking, and speech. Both the shared clinical features and frequent co-occurrence point to a close relationship between SSD and ASD. To further strength this relationship, it has been reported that about 30% of children and adolescents with COS had co-morbid ASD (<xref ref-type="bibr" rid="B4">4</xref>). In addition, the well-known difficulty to recognize social cues from the actions of others is tightly related to deficit in theory of mind that is a characteristic feature common to both SSD and ASD (<xref ref-type="bibr" rid="B5">5</xref>).</p>
<p>In this context, it is critically important to underscore that the negative symptoms of SSD are often more disabling and more resistant to treatment than the so-called positive ones, e.g., hallucinations and delusions (<xref ref-type="bibr" rid="B6">6</xref>). These negative symptoms include social avoidance and emotional flatness and might be regarded as closely linked to impairments in social communication and motivation. These so-called negative symptoms of SSD might be considered to fall within the same domain of social impairment as the social difficulties characteristic of ASD. Furthermore, the disorganized or abnormal behaviors characteristic of SSD include behaviors which would meet ASD Criterion B, e.g., repeated and stereotyped movements and verbal expressions, as to DSM-5. Other pathognomonic features common to both conditions include impairments in facial recognition and emotion processing (<xref ref-type="bibr" rid="B7">7</xref>, <xref ref-type="bibr" rid="B8">8</xref>). Patients with both ASD and SSD have been shown to have significant difficulties in interpreting social cues associated with eye gaze and deficits on theory of mind tasks—one of the hallmarks of ASD.</p>
<p>Autism spectrum disorders and SSD share biological underpinnings that may emerge in early neural development and unfold during subsequent childhood development (<xref ref-type="bibr" rid="B9">9</xref>). Abnormal neural development has been ascertained in cortical projection neurons from different brain areas including prefrontal and somatosensory regions in ASD and dorsolateral/ventrolateral prefrontal regions in SSD. It has to be mentioned that neurodevelopmental disorders are associated with known genetic abnormalities both in ASD and SSD phenotypes, as detailed in Table <xref ref-type="table" rid="T1">1</xref>. Furthermore, epigenetic effects and alterations in copy number variants (CNVs) have been reported to contribute to abnormalities of neural circuits associated with SSD and ASD (Table <xref ref-type="table" rid="T2">2</xref>). The risk of both disorders is increased by advanced paternal age and maternal infection/immune activation during pregnancy (<xref ref-type="bibr" rid="B10">10</xref>, <xref ref-type="bibr" rid="B11">11</xref>). These shared patterns suggest that the two spectra are likely to represent outcomes of common pathophysiological mechanisms. The next sections describe the E/I imbalance as a candidate mechanism possibly involved.</p>
<table-wrap id="T1" position="float">
<label>Table 1</label>
<caption>
<p><bold>Candidate genes validated in autism spectrum disorders (ASD) and schizophrenia spectrum disorders (SSD)</bold>.</p>
</caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="left" colspan="1" rowspan="1" valign="top">Gene</th>
<th align="left" colspan="1" rowspan="1" valign="top">Function</th>
<th align="left" colspan="1" rowspan="1" valign="top">Other phenotypes</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">RELN</td>
<td align="left" colspan="1" rowspan="1" valign="top">Neuronal migration, polarization</td>
<td align="left" colspan="1" rowspan="1" valign="top">Lissencephaly, Alzheimer’s disease</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">DISC1</td>
<td align="left" colspan="1" rowspan="1" valign="top">Neural development, synaptic plasticity, mammalian target of rapamycin (mTOR) regulation</td>
<td align="left" colspan="1" rowspan="1" valign="top">Depression, bipolar disorder</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">FOXP2</td>
<td align="left" colspan="1" rowspan="1" valign="top">Regulates DISC1, CTNAP2, language, and neural development</td>
<td align="left" colspan="1" rowspan="1" valign="top">Developmental verbal dyspraxia</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">BDNF</td>
<td align="left" colspan="1" rowspan="1" valign="top">Neurotrophic factor, regulates mTOR/AKT</td>
<td align="left" colspan="1" rowspan="1" valign="top">Alzheimer’s disease, Huntington disease</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">MECP2</td>
<td align="left" colspan="1" rowspan="1" valign="top">Epigenetic regulator</td>
<td align="left" colspan="1" rowspan="1" valign="top">Rett syndrome</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">UBE3A</td>
<td align="left" colspan="1" rowspan="1" valign="top">Epigenetic regulator</td>
<td align="left" colspan="1" rowspan="1" valign="top">Angelmann syndrome</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">NLGN3</td>
<td align="left" colspan="1" rowspan="1" valign="top">Postsynaptic component coupled with NRXN</td>
<td align="left" colspan="1" rowspan="1" valign="top">Undefined</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">NLG4</td>
<td align="left" colspan="1" rowspan="1" valign="top">Postsynaptic component coupled with NXRN</td>
<td align="left" colspan="1" rowspan="1" valign="top">ID</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">NRXN1</td>
<td align="left" colspan="1" rowspan="1" valign="top">Presynaptic component coupled with NXRN</td>
<td align="left" colspan="1" rowspan="1" valign="top">Pitt–Hopkins phenotype</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">SHANK3</td>
<td align="left" colspan="1" rowspan="1" valign="top">Postsynaptic protein in glutamatergic neuron</td>
<td align="left" colspan="1" rowspan="1" valign="top">Phelan–McDermid syndrome</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">CNTAP2</td>
<td align="left" colspan="1" rowspan="2" valign="top">Cell adhesion and differentiation</td>
<td align="left" colspan="1" rowspan="2" valign="top">ID, epilepsy, language impairment</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">CNTAP4</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">GRIN2B</td>
<td align="left" colspan="1" rowspan="1" valign="top">NMDA receptor subunit</td>
<td align="left" colspan="1" rowspan="1" valign="top">ID, epilepsy</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">NTGN1</td>
<td align="left" colspan="1" rowspan="1" valign="top">Axon guidance</td>
<td align="left" colspan="1" rowspan="1" valign="top">Bipolar disorder</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">GABRB3</td>
<td align="left" colspan="1" rowspan="2" valign="top">GABA receptor subunits</td>
<td align="left" colspan="1" rowspan="2" valign="top">Bipolar disorder</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">GABRA5</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">GAD</td>
<td align="left" colspan="1" rowspan="1" valign="top">Conversion of glutamate to GABA</td>
<td align="left" colspan="1" rowspan="1" valign="top">Epilepsy</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">CACNA1C</td>
<td align="left" colspan="1" rowspan="1" valign="top">Voltage-dependent calcium channel subunit</td>
<td align="left" colspan="1" rowspan="1" valign="top">Bipolar disorder, Brugada, and Timothy syndromes</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">SLC25A12</td>
<td align="left" colspan="1" rowspan="1" valign="top">Mitochondrial membrane, solute channel protein</td>
<td align="left" colspan="1" rowspan="1" valign="top">Mitochondrial disorders</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">OXTR/OXT</td>
<td align="left" colspan="1" rowspan="1" valign="top">Oxytocin receptor/oxytocin gene</td>
<td align="left" colspan="1" rowspan="1" valign="top">Undefined</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">ZNF804A</td>
<td align="left" colspan="1" rowspan="1" valign="top">Transcription regulator of PRSS16, COMT</td>
<td align="left" colspan="1" rowspan="1" valign="top">Bipolar disorders</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<p><italic>Modified by de Lacy and King (<xref ref-type="bibr" rid="B9">9</xref>)</italic>.</p>
<p><italic>ID, intellectual disability</italic>.</p>
</table-wrap-foot>
</table-wrap>
<table-wrap id="T2" position="float">
<label>Table 2</label>
<caption>
<p><bold>Copy number variants (CNVs) implicated in ASD and SSD</bold>.</p>
</caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="left" colspan="1" rowspan="1" valign="top">Region and type</th>
<th align="left" colspan="1" rowspan="1" valign="top">Candidate genes</th>
<th align="left" colspan="1" rowspan="1" valign="top">Phenotypes</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">1q21.1 Del</td>
<td align="left" colspan="1" rowspan="1" valign="top">Unidentified</td>
<td align="left" colspan="1" rowspan="1" valign="top">SCZ, ASD, ID, ADHD, deficit IGE</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">1q21.1 Dup</td>
<td align="left" colspan="1" rowspan="1" valign="top">Unidentified</td>
<td align="left" colspan="1" rowspan="1" valign="top">ASD, ID, ADHD</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">2p16.3 Del</td>
<td align="left" colspan="1" rowspan="1" valign="top">NRXN1</td>
<td align="left" colspan="1" rowspan="1" valign="top">SCZ, ASD, ID</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">3q29 Del</td>
<td align="left" colspan="1" rowspan="1" valign="top">PAK2</td>
<td align="left" colspan="1" rowspan="1" valign="top">ACZ, ID, ADHD</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">3q29 Dup</td>
<td align="left" colspan="1" rowspan="1" valign="top">Unidentified</td>
<td align="left" colspan="1" rowspan="1" valign="top">ID</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">15q11.2 Del</td>
<td align="left" colspan="1" rowspan="1" valign="top">CYF1P1</td>
<td align="left" colspan="1" rowspan="1" valign="top">ID, DD, SCZ, ASD, IGE, OCD, MDD</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">15q11-13 Dup</td>
<td align="left" colspan="1" rowspan="1" valign="top">GABRA5, GABRB3, GABG3, and others</td>
<td align="left" colspan="1" rowspan="1" valign="top">SCZ, ASD, ID, Ataxia</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">15q13.3 Del</td>
<td align="left" colspan="1" rowspan="1" valign="top">CHRNA7</td>
<td align="left" colspan="1" rowspan="1" valign="top">SCZ, ASD, ID</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">16p11.2 Del</td>
<td align="left" colspan="1" rowspan="1" valign="top">DOC2A, ERK1</td>
<td align="left" colspan="1" rowspan="1" valign="top">SCZ, ASD, ID, learning disorder</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">16p11.2 Dup</td>
<td align="left" colspan="1" rowspan="1" valign="top">DOC2A, ERK1</td>
<td align="left" colspan="1" rowspan="1" valign="top">SCZ, ASD, ID, DD</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">16p13.11 Del</td>
<td align="left" colspan="1" rowspan="1" valign="top">NDE1</td>
<td align="left" colspan="1" rowspan="1" valign="top">SCZ, ASD, ID</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">16p13.11 Dup</td>
<td align="left" colspan="1" rowspan="1" valign="top">NDE1</td>
<td align="left" colspan="1" rowspan="1" valign="top">SCZ, ASD, ID, ADHD, IGE</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">17q12</td>
<td align="left" colspan="1" rowspan="1" valign="top">Undefined</td>
<td align="left" colspan="1" rowspan="1" valign="top">SCZ, ASD, ID</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">22q11.2</td>
<td align="left" colspan="1" rowspan="1" valign="top">PRODH, COMT, DGCR6, TRX1</td>
<td align="left" colspan="1" rowspan="1" valign="top">SCZ, ASD, ID, epilepsy</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">22q11.21</td>
<td align="left" colspan="1" rowspan="1" valign="top">PRODH, COMT, DGCR6, TRX1</td>
<td align="left" colspan="1" rowspan="1" valign="top">ID, DD</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">22q13.3</td>
<td align="left" colspan="1" rowspan="1" valign="top">SHANK3</td>
<td align="left" colspan="1" rowspan="1" valign="top">ID, DD, ASD, SCZ</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<p><italic>Modified by de Lacy and King (<xref ref-type="bibr" rid="B9">9</xref>)</italic>.</p>
<p><italic>ID, intellectual disability; ADHD, attention-deficit hyperactivity disorder, DD, developmental delay; OCD, obsessive–compulsive disorder; MMDD, major depressive disorder; IGE, immunoglobulin E deficit</italic>.</p>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="S2">
<title>E/I Imbalance in ASD and SSD</title>
<p>An emerging hypothesis for the similarities in the social and cognitive disturbances associated with ASD and SSD is based on alterations in the ratio of excitatory to inhibitory cortical activity (E/I imbalance). Glutamate and GABA are, respectively, the two main neurotransmitters involved in excitatory and inhibitory signaling in the brain. Increased glutamatergic signaling alongside decreased GABAergic signaling would represent an E/I imbalance. Such imbalances may arise from disturbances in neural circuit formation or, abnormalities in the genes which code for proteins involved in these processes and linkage and association studies have been implicated in ASD and SSD (<xref ref-type="bibr" rid="B12">12</xref>). Postmortem studies have reported structural changes in both excitatory glutamatergic and inhibitory GABAergic circuits in individuals with ASD and SCZ (<xref ref-type="bibr" rid="B13">13</xref>–<xref ref-type="bibr" rid="B15">15</xref>).</p>
<p>In neurodevelopmental disorders, an E/I imbalance could arise directly through alterations in genes coding for glutamatergic receptors or synaptic proteins (<xref ref-type="bibr" rid="B16">16</xref>–<xref ref-type="bibr" rid="B18">18</xref>). The synapse organizers neurexins and their binding neuroligins are implicated in the formation and maintenance of excitatory and inhibitory synapses. Heterozygous deletions eliminating exons of the neurexin-1α gene in patients with ASD and SCZ have been detected and the functional significance of this recurrent deletion is still unclear. However, the availability of mice with deletion of the promoter and first exon of neurexin-1α provided evidence of the effects of neurexin-1α disruption on phenotypes relevant to ASD and SCZ and supported the role of neuroxins in neurodevelopmental disorders (<xref ref-type="bibr" rid="B19">19</xref>, <xref ref-type="bibr" rid="B20">20</xref>).</p>
<p>In addition to the synaptic dysfunction, there is increasing evidence that E/I balance is also modulated by glial mechanisms that regulate glutamate activity (<xref ref-type="bibr" rid="B21">21</xref>, <xref ref-type="bibr" rid="B22">22</xref>). Abnormalities in astrocyte gene expression in both ASD and SCZ have been detected (<xref ref-type="bibr" rid="B23">23</xref>), and reduced numbers of oligodendrocytes, impaired cell maturation, and altered gene expression of myelin/oligodendrocyte-related genes have been ascertained in SCZ (<xref ref-type="bibr" rid="B24">24</xref>). In turn, an increased number of activated microglia cells in adults with ASD have been found (<xref ref-type="bibr" rid="B25">25</xref>). As a result, glia deserves specific attention in the evaluation of E/I imbalance in these conditions.</p>
</sec>
<sec id="S3">
<title>ASD and E/I Imbalance</title>
<p>The net effect of changes in glutamatergic and GABAergic systems in ASD may be an overall increase in the ratio of excitation to inhibition (E/I). Such an increase is likely to be implicated in seizures, macrocephaly, and core ASD symptoms (<xref ref-type="bibr" rid="B26">26</xref>). The E–I ratio in neocortical structures is determined by pyramidal glutamatergic neurons and inhibitory GABAergic parvalbumin (PV)-positive interneurons that are modulated and fine-tuned by minicolumns (groups of functionally autonomous neurons whose afferent and efferent connections influence the functioning of microcircuits) which have been found to be abnormal in ASD (<xref ref-type="bibr" rid="B27">27</xref>, <xref ref-type="bibr" rid="B28">28</xref>). There are a number of candidate mechanisms for glutamatergic hyperactivity-driven hyperexcitability. Neuroligins (NL1–4) and neurexins (Nrxns 1–3) have been linked with ASD via point mutations and truncations, and chromosomal rearrangements have been identified in the region of interest (<xref ref-type="bibr" rid="B29">29</xref>–<xref ref-type="bibr" rid="B31">31</xref>). SHANK1, SHANK2, and SHANK3 are scaffolding proteins which influence the postsynaptic density of glutamatergic synapses and are of primary importance in ASD. SHANK3 is reported to be involved in Phelan–McDermid syndrome a form of ASD associated with moderate to severe intellectual disability (ID) and poor language skills (<xref ref-type="bibr" rid="B32">32</xref>). Regarding SHANK2 and SHANK1, they were found altered in ASD associated with mild ID as well as in high functioning individuals (<xref ref-type="bibr" rid="B33">33</xref>).</p>
<p>As to the mechanisms of GABAergic inhibitory dysfunction, the link with core ASD symptoms in humans is still under investigation. Deficit in binocular rivalry, a visual function that is thought to rely on the balance of excitation/inhibition in visual cortex has been observed in ASD individuals. The link between GABA and binocular rivalry dynamics was found specifically absent in ASD pointing to an insufficient GABA inhibitory function (<xref ref-type="bibr" rid="B34">34</xref>). Postmortem studies have provided evidence of alterations in GABAergic circuits in ASD individuals; there have been reports of significantly reduced GAD65/GAD67 levels in the parietal cortex and cerebellum (<xref ref-type="bibr" rid="B35">35</xref>).</p>
<p>Induced pluripotent stem cells (iPSCs) have been used to investigate putative abnormalities in neural substrate of individuals with ASD. Even if no known underlying genomic mutation could be identified in a new study herein presented, interestingly, transcriptome and gene network analyses revealed upregulation of genes involved in cell proliferation, neuronal differentiation, and synaptic formation. The main finding was that overexpression of the transcription factor FOXG1 was responsible for the overproduction of GABAergic neurons, shifting the E/I balance toward inhibition (<xref ref-type="bibr" rid="B36">36</xref>).</p>
</sec>
<sec id="S4">
<title>SSD and E/I Imbalance</title>
<p>Several postmortem studies detected lower levels of PV mRNA and GAD67, the principal synthesizing enzyme for GABA, in dorso-lateral-prefrontal cortex (DLPFC) PV neurons of patients with SCZ. Markers of GABA neurotransmission between chandelier neurons and their synaptic targets are altered in the DLPFC of subjects with SCZ (<xref ref-type="bibr" rid="B37">37</xref>, <xref ref-type="bibr" rid="B38">38</xref>).</p>
<p>NMDA receptors are ionotropic glutamate receptors involved in synaptic regulation of E/I balance and there are multiple subtypes of NMDA receptor with different functions and distributions (<xref ref-type="bibr" rid="B39">39</xref>). Dysfunction of NMDARs has been documented in SCZ both in experimental models and human studies. In the NMDA-hypofunction model of the disease, changes in E/I balance and the resulting changes in behaviors have been hypothesized (<xref ref-type="bibr" rid="B40">40</xref>). Disrupted NMDAR function is implicated in altered neurodevelopment and may play a role in the progression of symptoms for SCZ especially for cognitive deficits (<xref ref-type="bibr" rid="B41">41</xref>–<xref ref-type="bibr" rid="B43">43</xref>). NMDA receptor hypofunction has been proposed in ASD as well and the NR2A, NR2B, and NR2C genes abnormalities have been associated with ASD (<xref ref-type="bibr" rid="B44">44</xref>).</p>
<p>Remarkably, two <italic>de novo</italic> mutations in the <italic>GRIN2A</italic>-coded subunit of NMDA receptors have been detected in patients with SCZ and one <italic>de novo</italic> mutation in <italic>GRIN2B</italic>-coded subunit in a patient with ASD. Truncating mutations in <italic>GRIN2C, GRIN3A</italic>, and <italic>GRIN3B</italic> were identified in both patients and controls, but no truncating mutations were found in the <italic>GRIN1, GRIN2A, GRIN2B</italic>, and <italic>GRIN2D</italic> genes (<xref ref-type="bibr" rid="B45">45</xref>).</p>
<p>NRG1and ErbB4 genes deserve attention, are expressed at excitatory synapses, and regulate spine structure and function. ErbB4 deletion is associated with neurodevelopmental abnormalities that are consistent with SSD (<xref ref-type="bibr" rid="B46">46</xref>, <xref ref-type="bibr" rid="B47">47</xref>). The disrupted in SCZ 1 gene (<italic>DISC1</italic>) is another important candidate gene implicated at different levels of neurodevelopment through a scaffolding protein and different mutations have been detected in SCZ emphasizing its role (<xref ref-type="bibr" rid="B48">48</xref>, <xref ref-type="bibr" rid="B49">49</xref>).</p>
<p>E/I imbalance has been proposed as a mechanism for hallucinations, one of the main positive symptoms of SSD. Hallucinations have been linked to inhibitory deficits such as impaired GABA transmission unfolding in a series of abnormalities such as impaired NDMA receptor plasticity, reductions in gamma frequency oscillations, sensory cortical hyperactivity, and cognitive inhibition deficits. However, the mechanisms by which E/I dysfunctions at the cellular level might be linked to clinical symptoms and cognitive deficits remain unclear (<xref ref-type="bibr" rid="B50">50</xref>).</p>
<p>The 22q11 microdeletion syndrome is the most common CNV associated with SCZ as it is present in 1–2% of cases, further there is a very high association of the syndrome with SCZ, up to 30–40%. This elevated risk is not associated with any other neurogenetic syndrome. Social cognition is impaired in 22q11.2 deletion syndrome and remarkably this feature is correlated with psychotic symptoms. The role of this microdeletion as a potential contributor to E/I imbalance is undefined (<xref ref-type="bibr" rid="B51">51</xref>).</p>
</sec>
<sec id="S5">
<title>Convergent Pathways vs. Divergent Phenotype in ASD and SSD</title>
<p>Schizophrenia spectrum disorders and ASD have been described as polygenic disorders in which the onset and progression of disease are triggered by interactions among multiple susceptibility genes.</p>
<p>Overlaps of risk genes among ASD and SSD have been documented. Two lines of mutant mice with <italic>Shank3</italic> mutations linked to ASD and SSD have been documented with shared and distinct synaptic and behavioral phenotypes. Mice with the ASD-linked InsG3680 mutation manifest striatal synaptic transmission defects before weaning age and impaired juvenile social interaction, coinciding with the early onset of ASD symptoms. On the other hand, adult mice carrying the SCZ-linked R1117X mutation demonstrated synaptic defects in prefrontal cortex and social dominance behavior. This is a paradigmatic example of different alleles of the same gene that have distinct phenotypes at molecular, synaptic, and circuit levels which may inform exploration of these divergences in human patients (<xref ref-type="bibr" rid="B52">52</xref>).</p>
</sec>
<sec id="S6">
<title>Mammalian Target of Rapamycin (mTOR) Signaling in ASD and SSD</title>
<p>The mTOR pathway is directly involved in the physiological maintenance of the synaptic E/I ratio and is implicated in ASD by virtue of its role in upstream signaling and downstream regulatory mechanisms (<xref ref-type="bibr" rid="B12">12</xref>). Dysregulation of mTOR increases excitability and decreases inhibition thus contributing to E/I imbalance. mTOR activation is found in tuberous sclerosis complex mutations (TSC1/TSC2) occurring in tuberous sclerosis, which is frequently associated with ASD. Dysregulation of the mTOR pathway in these conditions provides clues to the molecular pathophysiology of ASD as the synaptic and cellular alterations involved may converge to produce the core social impairment of these disorders (<xref ref-type="bibr" rid="B53">53</xref>). In addition, mTOR inhibitor compounds have the potential to reverse many of the behavioral and neurophysiological abnormalities associated with ASD (<xref ref-type="bibr" rid="B54">54</xref>).</p>
<p>Recent investigations have linked SSD to the mTOR signaling cascade (<xref ref-type="bibr" rid="B55">55</xref>). Dysfunction of diverse upstream activators and environmental stressors, that have been previously implicated in SCZ, can lead to either over-activation or inhibition of the signaling pathway. Alterations in GABA signaling may be involved in the dysfunction of inhibitory circuits in SSD through the DISC1–Akt–mTOR pathway. As well, a putative depression of mTOR signaling with possible variation between and within brain regions affecting neuronal functioning in variable fashion has been proposed. Consistently, a preponderant decrease in glutamatergic activity with respect to GABAergic activity has been reported (<xref ref-type="bibr" rid="B56">56</xref>). In this functional and still undefined background, abnormal synaptic function may be related to positive and negative symptoms of SSD (<xref ref-type="bibr" rid="B57">57</xref>). Lastly, mTOR signaling undergoes variations as neurodevelopment unfold and environment plays a significant role especially through early life experiences that needs to be thoroughly considered (<xref ref-type="bibr" rid="B58">58</xref>).</p>
</sec>
<sec id="S7">
<title>Final Remarks and Future Directions</title>
<p>There is epidemiological, clinical, neurobiological, and genetic evidence for a close relationship between ASD and SSD, and significant overlap in symptoms is frequently observed; however, there are also differences in clinical presentation, behavioral phenotype, and developmental trajectory.</p>
<p>The complex pathways that control E/I balance provide a framework for understanding how different genetic alterations implicated in these two distinct disorders can interact to disrupt excitatory and inhibitory neuronal function, neuronal circuit organization thus eventually influence complex social and cognitive behaviors. Nonetheless, it has to be clearly stated that current knowledge of the mechanistic relationships between E/I imbalance and the two spectrum disorders is still exploratory and need further evidence. The ways in which these shared mechanisms contribute to specific phenotypes such as ASD and SSD are still largely unknown. There are a number of open questions that need to be addressed such as whether there is a critical period for an E/I imbalance that mediates ASD- and SSD-associated behavior, or whether the E/I imbalance is circuit specific. Furthermore, an E/I imbalance may arise not only from synaptic dysfunction but also from altered cell fate that can lead to abnormal proportions of inhibitory and excitatory cells.</p>
<p>Shedding light on the shared functions of candidate genes for involvement in ASD and SSD is the key to translating genetic findings into descriptions of developmental and clinical subtypes. As to neuronal dysfunction hypothesized, abnormalities might be specific affecting only a subset of synapses in a selective group of neurons responsible of distinct symptoms but all that is still an hypothesis as evidence on the brain circuits potentially involved is lacking.</p>
<p>Research domain criteria (RDoC) project seems particularly indicated to this scope as it is directed to implement all the above level of understanding. One of the main purpose is to investigate mental illness through the dimensional approach to the fundamental components of behavior, through individual symptoms or symptom clusters, that cut across diagnoses, in this case specifically in ASD and SSD domains (<xref ref-type="bibr" rid="B59">59</xref>). Aim and legacy of RDoC novel approach is to build a research perspective that reflects advances in genetics, neuroscience, and behavioral science to provide a foundation for precision diagnosis and treatment of complex mental disorders such as those herein examined. The details obtained by the use of RDoC matrix likely will help to shed light on ASD and SSD relationships as well as on the longitudinal monitoring of emerging convergent and divergent symptoms of the two spectra (<xref ref-type="bibr" rid="B60">60</xref>).</p>
<p>It should also be noted that there is a subset of individuals with complex neurodevelopmental disorders whose symptoms span multiple functional domains including cognition and social communication. These individuals do not fit under any of the current diagnostic labels listed under ASD and SSD and further research through an RDoC approach holds promise to describe the specific biobehavioral profiles and thus eventually establish the diagnostic category in which they should be included. Consistent developmental designs are awaited to capture changes in the underlying neural circuitry, molecular pathways including E/I balance, and other biological components in ASD and SSD, relating them to changes in their corresponding cognitive and affective determinants as they emerge over time and alter behavior under the influencing role of environment.</p>
</sec>
<sec id="S8">
<title>Author Contributions</title>
<p>RC and Mauro Pallagrosi equally participated in the substantial contribution to the conception or design of the work; drafted the work and revised it critically for important intellectual content; approved the final version to be published; and are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.</p>
</sec>
<sec id="S9">
<title>Conflict of Interest Statement</title>
<p>The authors declare that the research was conducted in the absence of any commercial or financial relationship that could be constructed as a potential conflict of interest.</p>
</sec>
</body>
<back>
<sec id="S10">
<title>Funding</title>
<p>This was a self-funded manuscript.</p>
</sec>
<ref-list>
<title>References</title>
<ref id="B1">
<label>1</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hommer</surname><given-names>RE</given-names></name><name><surname>Swedo</surname><given-names>SE</given-names></name></person-group>
<article-title>Schizophrenia and autism-related disorders</article-title>. <source/>Schizophr Bull (<year>2015</year>) <volume>41</volume>(<issue>2</issue>):<fpage>313</fpage>–<lpage>4</lpage>.<pub-id pub-id-type="doi">10.1093/schbul/sbu188</pub-id><pub-id pub-id-type="pmid">25634913</pub-id></mixed-citation>
</ref>
<ref id="B2">
<label>2</label>
<mixed-citation publication-type="book"><collab>American Psychiatric Association</collab>. <source/>Diagnostic and Statistical Manual of Mental Disorders. <edition>5th ed</edition>
<publisher-loc>Washington, DC</publisher-loc>: <publisher-name>American Psychiatric Association</publisher-name> (<year>2013</year>).</mixed-citation>
</ref>
<ref id="B3">
<label>3</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rapoport</surname><given-names>J</given-names></name><name><surname>Chavez</surname><given-names>A</given-names></name><name><surname>Greenstein</surname><given-names>D</given-names></name><name><surname>Addington</surname><given-names>A</given-names></name><name><surname>Gogtay</surname><given-names>N</given-names></name></person-group>. <article-title>Autism spectrum disorders and childhood-onset schizophrenia: clinical and biological contributions to a relation revisited</article-title>. <source/>J Am Acad Child Adolesc Psychiatry (<year>2009</year>) <volume>48</volume>(<issue>1</issue>):<fpage>10</fpage>–<lpage>8</lpage>.<pub-id pub-id-type="doi">10.1097/CHI.0b013e31818b1c63</pub-id><pub-id pub-id-type="pmid">19218893</pub-id></mixed-citation>
</ref>
<ref id="B4">
<label>4</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Driver</surname><given-names>DI</given-names></name><name><surname>Gogtay</surname><given-names>N</given-names></name><name><surname>Rapoport</surname><given-names>J</given-names></name></person-group>. <article-title>Childhood onset schizophrenia and early onset schizophrenia spectrum disorders</article-title>. <source/>Child Adolesc Psychiatr Clin N Am (<year>2013</year>) <volume>22</volume>(<issue>4</issue>):<fpage>539</fpage>–<lpage>55</lpage>.<pub-id pub-id-type="doi">10.1016/j.chc.2013.04.001</pub-id><pub-id pub-id-type="pmid">24012072</pub-id></mixed-citation>
</ref>
<ref id="B5">
<label>5</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>King</surname><given-names>BH</given-names></name><name><surname>Lord</surname><given-names>C</given-names></name></person-group>. <article-title>Is schizophrenia on the autism spectrum?</article-title>
<source/>Brain Res (<year>2011</year>) <volume>1380</volume>:<fpage>34</fpage>–<lpage>41</lpage>.<pub-id pub-id-type="doi">10.1016/j.brainres.2010.11.031</pub-id><pub-id pub-id-type="pmid">21078305</pub-id></mixed-citation>
</ref>
<ref id="B6">
<label>6</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cochran</surname><given-names>DM</given-names></name><name><surname>Dvir</surname><given-names>Y</given-names></name><name><surname>Frazier</surname><given-names>JA</given-names></name></person-group>
<article-title>‘Autism-plus’ spectrum disorders: intersection with psychosis and the schizophrenia spectrum</article-title>. <source/>Child Adolesc Psychiatr Clin N Am (<year>2013</year>) <volume>22</volume>(<issue>4</issue>):<fpage>609</fpage>–<lpage>27</lpage>.<pub-id pub-id-type="doi">10.1016/j.chc.2013.04.005</pub-id><pub-id pub-id-type="pmid">24012076</pub-id></mixed-citation>
</ref>
<ref id="B7">
<label>7</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marwick</surname><given-names>K</given-names></name><name><surname>Hall</surname><given-names>J</given-names></name></person-group>
<article-title>Social cognition in schizophrenia: a review of face processing</article-title>. <source/>Br Med Bull (<year>2008</year>) <volume>88</volume>(<issue>1</issue>):<fpage>3</fpage>–<lpage>58</lpage>.<pub-id pub-id-type="doi">10.1093/bmb/ldn035</pub-id></mixed-citation>
</ref>
<ref id="B8">
<label>8</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sasson</surname><given-names>NJ</given-names></name><name><surname>Pinkham</surname><given-names>AE</given-names></name><name><surname>Weittenhiller</surname><given-names>LP</given-names></name><name><surname>Faso</surname><given-names>DJ</given-names></name><name><surname>Simpson</surname><given-names>C</given-names></name></person-group>. <article-title>Context effects on facial affect recognition in schizophrenia and autism: behavioral and eye-tracking evidence</article-title>. <source/>Schizophr Bull (<year>2016</year>) <volume>42</volume>(<issue>3</issue>):<fpage>675</fpage>–<lpage>8</lpage>.<pub-id pub-id-type="doi">10.1093/schbul/sbv176.3</pub-id><pub-id pub-id-type="pmid">26645375</pub-id></mixed-citation>
</ref>
<ref id="B9">
<label>9</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Lacy</surname><given-names>N</given-names></name><name><surname>King</surname><given-names>BH</given-names></name></person-group>. <article-title>Revisiting the relationship between autism and schizophrenia: toward an integrated neurobiology</article-title>. <source/>Annu Rev Clin Psychol (<year>2013</year>) <volume>9</volume>:<fpage>555</fpage>–<lpage>87</lpage>.<pub-id pub-id-type="doi">10.1146/annurev-clinpsy-050212-185627</pub-id><pub-id pub-id-type="pmid">23537488</pub-id></mixed-citation>
</ref>
<ref id="B10">
<label>10</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McGrath</surname><given-names>JJ</given-names></name><name><surname>Petersen</surname><given-names>L</given-names></name><name><surname>Agerbo</surname><given-names>E</given-names></name><name><surname>Mors</surname><given-names>O</given-names></name><name><surname>Mortensen</surname><given-names>PB</given-names></name><name><surname>Pedersen</surname><given-names>CB</given-names></name></person-group>. <article-title>A comprehensive assessment of parental age and psychiatric disorders</article-title>. <source/>JAMA Psychiatry (<year>2014</year>) <volume>71</volume>(<issue>3</issue>):<fpage>301</fpage>–<lpage>9</lpage>.<pub-id pub-id-type="doi">10.1001/jamapsychiatry.2013.4081</pub-id><pub-id pub-id-type="pmid">24452535</pub-id></mixed-citation>
</ref>
<ref id="B11">
<label>11</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Knuesel</surname><given-names>I</given-names></name><name><surname>Chicha</surname><given-names>L</given-names></name><name><surname>Britschgi</surname><given-names>M</given-names></name><name><surname>Schobel</surname><given-names>SA</given-names></name><name><surname>Bodmer</surname><given-names>M</given-names></name><name><surname>Hellings</surname><given-names>JA</given-names></name><etal></etal></person-group>
<article-title>Maternal immune activation and abnormal brain development across CNS disorders</article-title>. <source/>Nat Rev Neurol (<year>2014</year>) <volume>10</volume>(<issue>11</issue>):<fpage>643</fpage>–<lpage>60</lpage>.<pub-id pub-id-type="doi">10.1038/nrneurol.2014.187</pub-id><pub-id pub-id-type="pmid">25311587</pub-id></mixed-citation>
</ref>
<ref id="B12">
<label>12</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gao</surname><given-names>R</given-names></name><name><surname>Penzes</surname><given-names>P</given-names></name></person-group>. <article-title>Common mechanisms of excitatory and inhibitory imbalance in schizophrenia and autism spectrum disorders</article-title>. <source/>Curr Mol Med (<year>2015</year>) <volume>15</volume>(<issue>2</issue>):<fpage>146</fpage>–<lpage>67</lpage>.<pub-id pub-id-type="doi">10.2174/1566524015666150303003028</pub-id><pub-id pub-id-type="pmid">25732149</pub-id></mixed-citation>
</ref>
<ref id="B13">
<label>13</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chattopadhyaya</surname><given-names>B</given-names></name><name><surname>Cristo</surname><given-names>GD</given-names></name></person-group>. <article-title>GABAergic circuit dysfunctions in neurodevelopmental disorders</article-title>. <source/>Front Psychiatry (<year>2012</year>) <volume>3</volume>:<fpage>51</fpage>.<pub-id pub-id-type="doi">10.3389/fpsyt.2012.00051</pub-id><pub-id pub-id-type="pmid">22666213</pub-id></mixed-citation>
</ref>
<ref id="B14">
<label>14</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Glausier</surname><given-names>JR</given-names></name><name><surname>Lewis</surname><given-names>DA</given-names></name></person-group>
<article-title>Dendritic spine pathology in schizophrenia</article-title>. <source/>Neuroscience (<year>2013</year>) <volume>251</volume>:<fpage>90</fpage>–<lpage>107</lpage>.<pub-id pub-id-type="doi">10.1016/j.neuroscience.2012.04.044</pub-id><pub-id pub-id-type="pmid">22546337</pub-id></mixed-citation>
</ref>
<ref id="B15">
<label>15</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hutsler</surname><given-names>JJ</given-names></name><name><surname>Zhang</surname><given-names>C</given-names></name></person-group>. <article-title>Increased dendritic spine densities on cortical projection neurons in autism spectrum disorders</article-title>. <source/>Brain Res (<year>2010</year>) <volume>1309</volume>:<fpage>83</fpage>–<lpage>94</lpage>.<pub-id pub-id-type="doi">10.1016/j.brainres.2009.09.120</pub-id><pub-id pub-id-type="pmid">19896929</pub-id></mixed-citation>
</ref>
<ref id="B16">
<label>16</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Silverman</surname><given-names>JL</given-names></name><name><surname>Smith</surname><given-names>DG</given-names></name><name><surname>Rizzo</surname><given-names>SJ</given-names></name><name><surname>Karras</surname><given-names>MN</given-names></name><name><surname>Turner</surname><given-names>SM</given-names></name><name><surname>Tolu</surname><given-names>SS</given-names></name><etal></etal></person-group>
<article-title>Negative allosteric modulation of the mGluR5 receptor reduces repetitive behaviors and rescues social deficits in mouse models of autism</article-title>. <source/>Sci Transl Med (<year>2012</year>) <volume>4</volume>(<issue>131</issue>):<fpage>131</fpage>–<lpage>51</lpage>.<pub-id pub-id-type="doi">10.1126/scitranslmed.3003501</pub-id><pub-id pub-id-type="pmid">22539775</pub-id></mixed-citation>
</ref>
<ref id="B17">
<label>17</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Silverman</surname><given-names>JL</given-names></name><name><surname>Pride</surname><given-names>MC</given-names></name><name><surname>Hayes</surname><given-names>JE</given-names></name><name><surname>Puhger</surname><given-names>KR</given-names></name><name><surname>Butler-Struben</surname><given-names>HM</given-names></name><name><surname>Baker</surname><given-names>S</given-names></name><etal></etal></person-group>
<article-title>GABAB receptor agonist r-baclofen reverses social deficits and reduces repetitive behavior in two mouse models of autism</article-title>. <source/>Neuropsychopharmacology (<year>2015</year>) <volume>40</volume>(<issue>9</issue>):<fpage>2228</fpage>–<lpage>39</lpage>.<pub-id pub-id-type="doi">10.1038/npp.2015.66</pub-id><pub-id pub-id-type="pmid">25754761</pub-id></mixed-citation>
</ref>
<ref id="B18">
<label>18</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Spooren</surname><given-names>W</given-names></name><name><surname>Lindemann</surname><given-names>L</given-names></name><name><surname>Ghosh</surname><given-names>A</given-names></name><name><surname>Santarelli</surname><given-names>L</given-names></name></person-group>. <article-title>Synapse dysfunction in autism: a molecular medicine approach to drug discovery in neurodevelopmental disorders</article-title>. <source/>Trends Pharmacol Sci (<year>2012</year>) <volume>33</volume>(<issue>12</issue>):<fpage>669</fpage>–<lpage>84</lpage>.<pub-id pub-id-type="doi">10.1016/j.tips.2012.09.004</pub-id><pub-id pub-id-type="pmid">23084458</pub-id></mixed-citation>
</ref>
<ref id="B19">
<label>19</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reichelt</surname><given-names>AC</given-names></name><name><surname>Rodgers</surname><given-names>RJ</given-names></name><name><surname>Clapcote</surname><given-names>SJ</given-names></name></person-group>. <article-title>The role of neurexins in schizophrenia and autistic spectrum disorder</article-title>. <source/>Neuropharmacology (<year>2012</year>) <volume>62</volume>(<issue>3</issue>):<fpage>1519</fpage>–<lpage>26</lpage>.<pub-id pub-id-type="doi">10.1016/j.neuropharm.2011.01.024</pub-id><pub-id pub-id-type="pmid">21262241</pub-id></mixed-citation>
</ref>
<ref id="B20">
<label>20</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grayton</surname><given-names>HM</given-names></name><name><surname>Missler</surname><given-names>M</given-names></name><name><surname>Collier</surname><given-names>DA</given-names></name><name><surname>Fernandes</surname><given-names>C</given-names></name></person-group>
<article-title>Altered social behaviours in neurexin 1alpha knockout mice resemble core symptoms in neurodevelopmental disorders</article-title>. <source/>PLoS One (<year>2013</year>) <volume>8</volume>:<fpage>e67114</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0067114</pub-id><pub-id pub-id-type="pmid">23840597</pub-id></mixed-citation>
</ref>
<ref id="B21">
<label>21</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Di Benedetto</surname><given-names>B</given-names></name><name><surname>Rupprecht</surname><given-names>R</given-names></name></person-group>. <article-title>Targeting glia cells: novel perspectives for the treatment of neuropsychiatric diseases</article-title>. <source/>Curr Neuropharmacol (<year>2013</year>) <volume>11</volume>:<fpage>171</fpage>–<lpage>85</lpage>.<pub-id pub-id-type="doi">10.2174/1570159X11311020004</pub-id><pub-id pub-id-type="pmid">23997752</pub-id></mixed-citation>
</ref>
<ref id="B22">
<label>22</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Durieux</surname><given-names>AMS</given-names></name><name><surname>Fernandes</surname><given-names>C</given-names></name><name><surname>Murphy</surname><given-names>D</given-names></name><name><surname>Labouesse</surname><given-names>MA</given-names></name><name><surname>Giovanoli</surname><given-names>S</given-names></name><name><surname>Meyer</surname><given-names>U</given-names></name><etal></etal></person-group>
<article-title>Targeting glia with N-acetylcysteine modulates brain glutamate and behaviors relevant to neurodevelopmental disorders in C57BL/6J mice</article-title>. <source/>Front Behav Neurosci (<year>2015</year>) <volume>9</volume>:<fpage>343</fpage>.<pub-id pub-id-type="doi">10.3389/fnbeh.2015.00343</pub-id><pub-id pub-id-type="pmid">26696857</pub-id></mixed-citation>
</ref>
<ref id="B23">
<label>23</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fatemi</surname><given-names>SH</given-names></name><name><surname>Reutiman</surname><given-names>TJ</given-names></name><name><surname>Folsom</surname><given-names>TD</given-names></name><name><surname>Thuras</surname><given-names>PD</given-names></name></person-group>. <article-title>GABA(A) receptor downregulation in brains of subjects with autism</article-title>. <source/>J Autism Dev Disord (<year>2009</year>) <volume>39</volume>(<issue>2</issue>):<fpage>223</fpage>–<lpage>30</lpage>.<pub-id pub-id-type="doi">10.1007/s10803-008-0646-7</pub-id><pub-id pub-id-type="pmid">18821008</pub-id></mixed-citation>
</ref>
<ref id="B24">
<label>24</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bernstein</surname><given-names>HG</given-names></name><name><surname>Steiner</surname><given-names>J</given-names></name><name><surname>Guest</surname><given-names>PC</given-names></name><name><surname>Dobrowolny</surname><given-names>H</given-names></name><name><surname>Bogerts</surname><given-names>B</given-names></name></person-group>. <article-title>Glial cells as key players in schizophrenia pathology: recent insights and concepts of therapy</article-title>. <source/>Schizophr Res (<year>2015</year>) <volume>161</volume>(<issue>1</issue>):<fpage>4</fpage>–<lpage>18</lpage>.<pub-id pub-id-type="doi">10.1016/j.schres.2014.03.035</pub-id><pub-id pub-id-type="pmid">24948484</pub-id></mixed-citation>
</ref>
<ref id="B25">
<label>25</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Onore</surname><given-names>C</given-names></name><name><surname>Careaga</surname><given-names>M</given-names></name><name><surname>Ashwood</surname><given-names>P</given-names></name></person-group>. <article-title>The role of immune dysfunction in the pathophysiology of autism</article-title>. <source/>Brain Behav Immun (<year>2012</year>) <volume>26</volume>(<issue>3</issue>):<fpage>383</fpage>–<lpage>92</lpage>.<pub-id pub-id-type="doi">10.1016/j.bbi.2011.08.007</pub-id><pub-id pub-id-type="pmid">21906670</pub-id></mixed-citation>
</ref>
<ref id="B26">
<label>26</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Uzunova</surname><given-names>G</given-names></name><name><surname>Pallanti</surname><given-names>S</given-names></name><name><surname>Hollander</surname><given-names>E</given-names></name></person-group>. <article-title>Excitatory/inhibitory imbalance in autism spectrum disorders: implications for interventions and therapeutics</article-title>. <source/>World J Biol Psychiatry (<year>2016</year>) <volume>17</volume>(<issue>3</issue>):<fpage>174</fpage>–<lpage>86</lpage>.<pub-id pub-id-type="doi">10.3109/15622975.2015.1085597</pub-id><pub-id pub-id-type="pmid">26469219</pub-id></mixed-citation>
</ref>
<ref id="B27">
<label>27</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hutsler</surname><given-names>JJ</given-names></name><name><surname>Casanova</surname><given-names>M</given-names></name></person-group>. <article-title>Review: cortical construction in autism spectrum disorder: columns, connectivity and the subplate</article-title>. <source/>Neuropathol Appl Neurobiol (<year>2016</year>) <volume>42</volume>(<issue>2</issue>):<fpage>115</fpage>–<lpage>34</lpage>.<pub-id pub-id-type="doi">10.1111/nan.12227</pub-id><pub-id pub-id-type="pmid">25630827</pub-id></mixed-citation>
</ref>
<ref id="B28">
<label>28</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Opris</surname><given-names>I</given-names></name><name><surname>Casanova</surname><given-names>MF</given-names></name></person-group>. <article-title>Prefrontal cortical minicolumn: from executive control to disrupted cognitive processing</article-title>. <source/>Brain (<year>2014</year>) <volume>137</volume>(<issue>7</issue>):<fpage>1863</fpage>–<lpage>75</lpage>.<pub-id pub-id-type="doi">10.1093/brain/awt359</pub-id><pub-id pub-id-type="pmid">24531625</pub-id></mixed-citation>
</ref>
<ref id="B29">
<label>29</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Etherton</surname><given-names>MR</given-names></name><name><surname>Tabuchi</surname><given-names>K</given-names></name><name><surname>Harma</surname><given-names>SM</given-names></name><name><surname>Ko</surname><given-names>J</given-names></name><name><surname>Sudhof</surname><given-names>TC</given-names></name></person-group>. <article-title>An autism-associated point mutation in the neuroligin cytoplasmic tail selectively impairs AMPA receptor-mediated synaptic transmission in hippocampus</article-title>. <source/>EMBO J (<year>2011</year>) <volume>30</volume>(<issue>14</issue>):<fpage>2908</fpage>–<lpage>19</lpage>.<pub-id pub-id-type="doi">10.1038/emboj.2011.182</pub-id><pub-id pub-id-type="pmid">21642956</pub-id></mixed-citation>
</ref>
<ref id="B30">
<label>30</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>C</given-names></name><name><surname>Milunsky</surname><given-names>JM</given-names></name><name><surname>Newton</surname><given-names>S</given-names></name><name><surname>Ko</surname><given-names>J</given-names></name><name><surname>Zhao</surname><given-names>G</given-names></name><name><surname>Maher</surname><given-names>TA</given-names></name><etal></etal></person-group>
<article-title>A neuroligin-4 missense mutation associated with autism impairs neuroligin-4 folding and endoplasmic reticulum export</article-title>. <source/>J Neurosci (<year>2009</year>) <volume>29</volume>(<issue>35</issue>):<fpage>10843</fpage>–<lpage>54</lpage>.<pub-id pub-id-type="doi">10.1523/JNEUROSCI.1248-09.2009</pub-id><pub-id pub-id-type="pmid">19726642</pub-id></mixed-citation>
</ref>
<ref id="B31">
<label>31</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gauthier</surname><given-names>J</given-names></name><name><surname>Siddiqui</surname><given-names>TJ</given-names></name><name><surname>Huashan</surname><given-names>P</given-names></name><name><surname>Yokomaku</surname><given-names>D</given-names></name><name><surname>Hamdan</surname><given-names>FF</given-names></name><name><surname>Champagne</surname><given-names>N</given-names></name><etal></etal></person-group>
<article-title>Truncating mutations in NRXN2 and NRXN1 in autism spectrum disorders and schizophrenia</article-title>. <source/>Hum Genet (<year>2011</year>) <volume>130</volume>(<issue>4</issue>):<fpage>563</fpage>–<lpage>73</lpage>.<pub-id pub-id-type="doi">10.1007/s00439-011-0975-z</pub-id><pub-id pub-id-type="pmid">21424692</pub-id></mixed-citation>
</ref>
<ref id="B32">
<label>32</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kolevzon</surname><given-names>A</given-names></name><name><surname>Angarita</surname><given-names>B</given-names></name><name><surname>Bush</surname><given-names>L</given-names></name><name><surname>Wang</surname><given-names>AT</given-names></name><name><surname>Frank</surname><given-names>Y</given-names></name><name><surname>Yang</surname><given-names>A</given-names></name><etal></etal></person-group>
<article-title>Phelan-McDermid syndrome: a review of the literature and practice parameters for medical assessment and monitoring</article-title>. <source/>J Neurodev Disord (<year>2014</year>) <volume>6</volume>:<fpage>39</fpage>.<pub-id pub-id-type="doi">10.1186/1866-1955-6-39</pub-id><pub-id pub-id-type="pmid">25784960</pub-id></mixed-citation>
</ref>
<ref id="B33">
<label>33</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leblond</surname><given-names>CS</given-names></name><name><surname>Nava</surname><given-names>C</given-names></name><name><surname>Polge</surname><given-names>A</given-names></name><name><surname>Jauthier</surname><given-names>G</given-names></name><name><surname>Huguet</surname><given-names>G</given-names></name><name><surname>Lumbroso</surname><given-names>S</given-names></name><etal></etal></person-group>
<article-title>Meta-analysis of SHANK mutations in autism spectrum disorders: a gradient of severity in cognitive impairments</article-title>. <source/>PLoS Genet (<year>2014</year>) <volume>10</volume>(<issue>9</issue>):<fpage>e1004580</fpage>.<pub-id pub-id-type="doi">10.1371/journal.pgen.1004580</pub-id><pub-id pub-id-type="pmid">25188300</pub-id></mixed-citation>
</ref>
<ref id="B34">
<label>34</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Robertson</surname><given-names>CE</given-names></name><name><surname>Ratai</surname><given-names>EM</given-names></name><name><surname>Kanwisher</surname><given-names>N</given-names></name></person-group>. <article-title>Reduced GABAergic action in the autistic brain</article-title>. <source/>Curr Biol (<year>2016</year>) <volume>26</volume>(<issue>1</issue>):<fpage>80</fpage>–<lpage>5</lpage>.<pub-id pub-id-type="doi">10.1016/j.cub.2015.11.019</pub-id><pub-id pub-id-type="pmid">26711497</pub-id></mixed-citation>
</ref>
<ref id="B35">
<label>35</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oblak</surname><given-names>AL</given-names></name><name><surname>Gibbs</surname><given-names>TT</given-names></name><name><surname>Blatt</surname><given-names>GJ</given-names></name></person-group>. <article-title>Decreased GABA(B) receptors in the cingulate cortex and fusiform gyrus in autism</article-title>. <source/>J Neurochem (<year>2010</year>) <volume>114</volume>(<issue>5</issue>):<fpage>1414</fpage>–<lpage>23</lpage>.<pub-id pub-id-type="doi">10.1111/j.1471-4159.2010.06858.x</pub-id><pub-id pub-id-type="pmid">20557420</pub-id></mixed-citation>
</ref>
<ref id="B36">
<label>36</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mariani</surname><given-names>J</given-names></name><name><surname>Coppola</surname><given-names>G</given-names></name><name><surname>Zhang</surname><given-names>P</given-names></name><name><surname>Abyzov</surname><given-names>A</given-names></name><name><surname>Provini</surname><given-names>L</given-names></name><name><surname>Tomasini</surname><given-names>L</given-names></name><etal></etal></person-group>
<article-title>FOXG1-dependent dysregulation of GABA/glutamate neuron differentiation in autism spectrum disorders</article-title>. <source/>Cell (<year>2015</year>) <volume>16</volume>(<issue>162</issue>):<fpage>375</fpage>–<lpage>90</lpage>.<pub-id pub-id-type="doi">10.1016/j.cell.2015.06.034</pub-id><pub-id pub-id-type="pmid">26186191</pub-id></mixed-citation>
</ref>
<ref id="B37">
<label>37</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lewis</surname><given-names>DA</given-names></name></person-group>
<article-title>The chandelier neuron in schizophrenia</article-title>. <source/>Dev Neurobiol (<year>2011</year>) <volume>1</volume>(<issue>71</issue>):<fpage>118</fpage>–<lpage>27</lpage>.<pub-id pub-id-type="doi">10.1002/dneu.20825</pub-id></mixed-citation>
</ref>
<ref id="B38">
<label>38</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gonzalez-Burgos</surname><given-names>G</given-names></name><name><surname>Lewis</surname><given-names>DA</given-names></name></person-group>. <article-title>GABA neurons and the mechanisms of network oscillations: implications for understanding cortical dysfunction in schizophrenia</article-title>. <source/>Schizophr Bull (<year>2008</year>) <volume>34</volume>(<issue>5</issue>):<fpage>944</fpage>–<lpage>61</lpage>.<pub-id pub-id-type="doi">10.1093/schbul/sbn070</pub-id><pub-id pub-id-type="pmid">18586694</pub-id></mixed-citation>
</ref>
<ref id="B39">
<label>39</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Paoletti</surname><given-names>R</given-names></name><name><surname>Bellone</surname><given-names>C</given-names></name><name><surname>Zhou</surname><given-names>Q</given-names></name></person-group>
<article-title>NMDA receptor subunit diversity: impact on receptor properties, synaptic plasticity and disease</article-title>. <source/>Nat Rev Neurosci (<year>2013</year>) <volume>14</volume>(<issue>6</issue>):<fpage>383</fpage>–<lpage>400</lpage>.<pub-id pub-id-type="doi">10.1038/nrn3504</pub-id><pub-id pub-id-type="pmid">23686171</pub-id></mixed-citation>
</ref>
<ref id="B40">
<label>40</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kehrer</surname><given-names>C</given-names></name><name><surname>Maziashvili</surname><given-names>N</given-names></name><name><surname>Dugladze</surname><given-names>T</given-names></name><name><surname>Gloveli</surname><given-names>T</given-names></name></person-group>. <article-title>Altered excitatory-inhibitory balance in the NMDA-hypofunction model of schizophrenia</article-title>. <source/>Front Mol Neurosci (<year>2008</year>) <volume>8</volume>(<issue>1</issue>):<fpage>6</fpage>.<pub-id pub-id-type="doi">10.3389/neuro.02.006.2008</pub-id><pub-id pub-id-type="pmid">18946539</pub-id></mixed-citation>
</ref>
<ref id="B41">
<label>41</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Balu</surname><given-names>DT</given-names></name></person-group>. <article-title>The NMDA receptor and schizophrenia: from pathophysiology to treatment</article-title>. <source/>Adv Pharmacol (<year>2016</year>) <volume>76</volume>:<fpage>351</fpage>–<lpage>82</lpage>.<pub-id pub-id-type="doi">10.1016/bs.apha.2016.01.006</pub-id><pub-id pub-id-type="pmid">27288082</pub-id></mixed-citation>
</ref>
<ref id="B42">
<label>42</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fromer</surname><given-names>M</given-names></name><name><surname>Pocklington</surname><given-names>AJ</given-names></name><name><surname>Kavanagh</surname><given-names>DH</given-names></name><name><surname>Williams</surname><given-names>HJ</given-names></name><name><surname>Dwyer</surname><given-names>S</given-names></name><name><surname>Gormley</surname><given-names>P</given-names></name><etal></etal></person-group>
<article-title>De novo mutations in schizophrenia implicate synaptic networks</article-title>. <source/>Nature (<year>2014</year>) <volume>506</volume>(<issue>7487</issue>):<fpage>179</fpage>–<lpage>84</lpage>.<pub-id pub-id-type="doi">10.1038/nature12929</pub-id><pub-id pub-id-type="pmid">24463507</pub-id></mixed-citation>
</ref>
<ref id="B43">
<label>43</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Snyder</surname><given-names>MA</given-names></name><name><surname>Gao</surname><given-names>WJ</given-names></name></person-group>. <article-title>NMDA hypofunction as a convergence point for progression and symptoms of schizophrenia</article-title>. <source/>Front Cell Neurosci (<year>2013</year>) <volume>27</volume>(<issue>7</issue>):<fpage>31</fpage>.<pub-id pub-id-type="doi">10.3389/fncel.2013.00031</pub-id><pub-id pub-id-type="pmid">23543703</pub-id></mixed-citation>
</ref>
<ref id="B44">
<label>44</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Voineagau</surname><given-names>I</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Johnston</surname><given-names>P</given-names></name><name><surname>Tian</surname><given-names>Y</given-names></name><name><surname>Horvath</surname><given-names>S</given-names></name><name><surname>Mill</surname><given-names>J</given-names></name><etal></etal></person-group>
<article-title>Transcriptomic analysis of autistic brain reveals convergent molecular pathology</article-title>. <source/>Nature (<year>2011</year>) <volume>474</volume>(<issue>7351</issue>):<fpage>380</fpage>–<lpage>4</lpage>.<pub-id pub-id-type="doi">10.1038/nature10110</pub-id><pub-id pub-id-type="pmid">21614001</pub-id></mixed-citation>
</ref>
<ref id="B45">
<label>45</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tarabeux</surname><given-names>J</given-names></name><name><surname>Kebir</surname><given-names>O</given-names></name><name><surname>Gauthier</surname><given-names>J</given-names></name><name><surname>Hamdan</surname><given-names>FF</given-names></name><name><surname>Xiong</surname><given-names>L</given-names></name><name><surname>Piton</surname><given-names>A</given-names></name><etal></etal></person-group>
<article-title>Rare mutations in N-methyl-<sc>d</sc>-aspartate glutamate receptors in autism spectrum disorders and schizophrenia</article-title>. <source/>Transl Psychiatry (<year>2011</year>) <volume>15</volume>(<issue>1</issue>):<fpage>e55</fpage>.<pub-id pub-id-type="doi">10.1038/tp.2011.52</pub-id><pub-id pub-id-type="pmid">22833210</pub-id></mixed-citation>
</ref>
<ref id="B46">
<label>46</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Banerjee</surname><given-names>A</given-names></name><name><surname>Macdonald</surname><given-names>ML</given-names></name><name><surname>Borgmann-Winter</surname><given-names>KE</given-names></name><name><surname>Hahn</surname><given-names>CG</given-names></name></person-group>. <article-title>Neuregulin 1-erbB4 pathway in schizophrenia: from genes to an interactome</article-title>. <source/>Brain Res Bull (<year>2010</year>) <volume>83</volume>(<issue>3–4</issue>):<fpage>132</fpage>–<lpage>9</lpage>.<pub-id pub-id-type="doi">10.1016/j.brainresbull.2010.04.011</pub-id><pub-id pub-id-type="pmid">20433909</pub-id></mixed-citation>
</ref>
<ref id="B47">
<label>47</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Perez-Garcia</surname><given-names>CG</given-names></name></person-group>. <article-title>ErbB4 in laminated brain structures: a neurodevelopmental approach to schizophrenia</article-title>. <source/>Front Cell Neurosci (<year>2015</year>) <volume>18</volume>(<issue>9</issue>):<fpage>472</fpage>.<pub-id pub-id-type="doi">10.3389/fncel.2015.00472</pub-id><pub-id pub-id-type="pmid">26733804</pub-id></mixed-citation>
</ref>
<ref id="B48">
<label>48</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mackie</surname><given-names>S</given-names></name><name><surname>Millar</surname><given-names>JK</given-names></name><name><surname>Porteous</surname><given-names>DJ</given-names></name></person-group>
<article-title>Role of DISC1 in neural development and <italic>schizophrenia</italic></article-title>. <source/>Curr Opin Neurobiol (<year>2007</year>) <volume>17</volume>(<issue>1</issue>):<fpage>95</fpage>–<lpage>102</lpage>.<pub-id pub-id-type="doi">10.1016/j.conb.2007.01.007</pub-id><pub-id pub-id-type="pmid">17258902</pub-id></mixed-citation>
</ref>
<ref id="B49">
<label>49</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bradshaw</surname><given-names>NJ</given-names></name><name><surname>DJ Porteous</surname><given-names>DJ</given-names></name></person-group>. <article-title>DISC1-binding proteins in neural development, signalling and schizophrenia</article-title>. <source/>Neuropharmacology (<year>2012</year>) <volume>62</volume>(<issue>3</issue>):<fpage>1230</fpage>–<lpage>41</lpage>.<pub-id pub-id-type="doi">10.1016/j.neuropharm.2010.12.027</pub-id><pub-id pub-id-type="pmid">21195721</pub-id></mixed-citation>
</ref>
<ref id="B50">
<label>50</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jardri</surname><given-names>R</given-names></name><name><surname>Hugdahl</surname><given-names>K</given-names></name><name><surname>Hughes</surname><given-names>M</given-names></name><name><surname>Brunelin</surname><given-names>J</given-names></name><name><surname>Waters</surname><given-names>F</given-names></name><name><surname>Alderson-Day</surname><given-names>B</given-names></name><etal></etal></person-group>
<article-title>Are hallucinations due to an imbalance between excitatory and inhibitory influences on the brain?</article-title>
<source/>Schizophr Bull (<year>2016</year>) <volume>42</volume>(<issue>5</issue>):<fpage>1124</fpage>–<lpage>34</lpage>.<pub-id pub-id-type="doi">10.1093/schbul/sbw075</pub-id><pub-id pub-id-type="pmid">27261492</pub-id></mixed-citation>
</ref>
<ref id="B51">
<label>51</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schneider</surname><given-names>M</given-names></name><name><surname>Debbane</surname><given-names>M</given-names></name><name><surname>Bassett</surname><given-names>AS</given-names></name><name><surname>Chow</surname><given-names>EW</given-names></name><name><surname>Fung</surname><given-names>WL</given-names></name><name><surname>van den Bree</surname><given-names>M</given-names></name><etal></etal></person-group>
<article-title>Psychiatric disorders from childhood to adulthood in 22q11.2 deletion syndrome: results from the International Consortium on Brain and Behavior in 22q11.2 Deletion Syndrome</article-title>. <source/>Am J Psychiatry (<year>2014</year>) <volume>171</volume>(<issue>6</issue>):<fpage>627</fpage>–<lpage>39</lpage>.<pub-id pub-id-type="doi">10.1176/appi.ajp.2013.13070864</pub-id><pub-id pub-id-type="pmid">24577245</pub-id></mixed-citation>
</ref>
<ref id="B52">
<label>52</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>Y</given-names></name><name><surname>Kaiser</surname><given-names>T</given-names></name><name><surname>Monteiro</surname><given-names>P</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Van der Goes</surname><given-names>MS</given-names></name><name><surname>Wang</surname><given-names>D</given-names></name><etal></etal></person-group>
<article-title>Mice with Shank3 mutations associated with ASD and schizophrenia display both shared and distinct defects</article-title>. <source/>Neuron (<year>2016</year>) <volume>89</volume>(<issue>1</issue>):<fpage>147</fpage>–<lpage>62</lpage>.<pub-id pub-id-type="doi">10.1016/j.neuron.2015.11.023</pub-id><pub-id pub-id-type="pmid">26687841</pub-id></mixed-citation>
</ref>
<ref id="B53">
<label>53</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sato</surname><given-names>A</given-names></name></person-group>. <article-title>mTOR, a potential target to treat autism spectrum disorder</article-title>. <source/>CNS Neurol Disord Drug Targets (<year>2016</year>) <volume>15</volume>(<issue>5</issue>):<fpage>533</fpage>–<lpage>43</lpage>.<pub-id pub-id-type="doi">10.2174/1871527315666160413120638</pub-id><pub-id pub-id-type="pmid">27071790</pub-id></mixed-citation>
</ref>
<ref id="B54">
<label>54</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Doering</surname><given-names>LC</given-names></name></person-group>
<article-title>Reversing autism by targeting downstream mTOR signaling</article-title>. <source/>Front Cell Neurosci (<year>2013</year>) <volume>7</volume>:<fpage>28</fpage><pub-id pub-id-type="doi">10.3389/fncel.2013.00028</pub-id><pub-id pub-id-type="pmid">23533374</pub-id></mixed-citation>
</ref>
<ref id="B55">
<label>55</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gururajan</surname><given-names>A</given-names></name><name><surname>van den Buuse</surname><given-names>M</given-names></name></person-group>. <article-title>Is the mTOR-signalling cascade disrupted in schizophrenia?</article-title>
<source/>J Neurochem (<year>2014</year>) <volume>129</volume>(<issue>3</issue>):<fpage>377</fpage>–<lpage>87</lpage>.<pub-id pub-id-type="doi">10.1111/jnc.12622</pub-id><pub-id pub-id-type="pmid">24266366</pub-id></mixed-citation>
</ref>
<ref id="B56">
<label>56</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weston</surname><given-names>MC</given-names></name><name><surname>Chen</surname><given-names>H</given-names></name><name><surname>Swann</surname><given-names>JW</given-names></name></person-group>. <article-title>Multiple roles for mammalian target of rapamycin signaling in both glutamatergic and GABAergic synaptic transmission</article-title>. <source/>J Neurosci (<year>2012</year>) <volume>32</volume>(<issue>33</issue>):<fpage>11441</fpage>–<lpage>52</lpage>.<pub-id pub-id-type="doi">10.1523/JNEUROSCI.1283-12.2012</pub-id><pub-id pub-id-type="pmid">22895726</pub-id></mixed-citation>
</ref>
<ref id="B57">
<label>57</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fatemi</surname><given-names>SH</given-names></name><name><surname>Folsom</surname><given-names>TD</given-names></name></person-group>. <article-title>The neurodevelopmental hypothesis of schizophrenia, revisited</article-title>. <source/>Schizophr Bull (<year>2009</year>) <volume>35</volume>(<issue>3</issue>):<fpage>528</fpage>–<lpage>48</lpage>.<pub-id pub-id-type="doi">10.1093/schbul/sbn187</pub-id><pub-id pub-id-type="pmid">19223657</pub-id></mixed-citation>
</ref>
<ref id="B58">
<label>58</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Costa-Mattioli</surname><given-names>M</given-names></name><name><surname>Monteggia</surname><given-names>LM</given-names></name></person-group>. <article-title>mTOR complexes in neurodevelopmental and neuropsychiatric disorders</article-title>. <source/>Nat Neurosci (<year>2013</year>) <volume>16</volume>(<issue>11</issue>):<fpage>1537</fpage>–<lpage>43</lpage>.<pub-id pub-id-type="doi">10.1038/nn.3546</pub-id><pub-id pub-id-type="pmid">24165680</pub-id></mixed-citation>
</ref>
<ref id="B59">
<label>59</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Garvey</surname><given-names>M</given-names></name><name><surname>Avenevoli</surname><given-names>S</given-names></name><name><surname>Anderson</surname><given-names>K</given-names></name></person-group>. <article-title>The National Institute of Mental Health research domain criteria and clinical research in child and adolescent psychiatry</article-title>. <source/>J Am Acad Child Adolesc Psychiatry (<year>2016</year>) <volume>55</volume>(<issue>2</issue>):<fpage>93</fpage>–<lpage>8</lpage>.<pub-id pub-id-type="doi">10.1016/j.jaac.2015.11.002</pub-id><pub-id pub-id-type="pmid">26802775</pub-id></mixed-citation>
</ref>
<ref id="B60">
<label>60</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cuthbert</surname><given-names>BN</given-names></name></person-group>
<article-title>The RDoC framework: facilitating transition from ICD/DSM to dimensional approaches that integrate neuroscience and psychopathology</article-title>. <source/>World Psychiatry (<year>2014</year>) <volume>13</volume>(<issue>1</issue>):<fpage>28</fpage>–<lpage>35</lpage>.<pub-id pub-id-type="doi">10.1002/wps.20087</pub-id><pub-id pub-id-type="pmid">24497240</pub-id></mixed-citation>
</ref>
</ref-list>
</back>
</article>
</pmc-articleset>